Published on in Vol 5, No 2 (2017): February

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Earle E Bain 1*, MD;  Laura Shafner 2*, MSc;  David P Walling 3*, PhD;  Ahmed A Othman 1*, PhD;  Christy Chuang-Stein 4*, PhD;  John Hinkle 5*, PhD;  Adam Hanina 2*, MBA

1 AbbVie Inc. , North Chicago, IL, US

2 AiCure, LLC , New York, NY, US

3 CNS Network, LLC , Garden Grove, CA, US

4 Chuang-Stein Consulting , Kalamazoo, MI, US

5 EarlyPhase Sciences, Inc. , Cary, NC, US

*all authors contributed equally

Corresponding Author: